Cours suspendu

Autres langues MicroPort Scientific Corporation

Actions

853 KYG608371046

Equipement et technologie médicale avancés

Marché Fermé - Hong Kong S.E. 10:08:48 31/08/2026			Varia. 5j.	Varia. 1 janv.
6,075 ^HKD	-2,64%		-.--%	-43,85%

31/08	MicroPort Scientific Corporation reporte la publication de ses résultats financiers pour le semestre clos le 30 juin 2026	CI
28/08	MicroPort Scientific Corporation annonce des changements au sein de son conseil d'administration et de ses comités, effectifs au 28 août 2026	CI

Autres langues

08/09	MicroPort Scientific : Artemis Dream® Intracranial Sirolimus-Eluting Stent System Enters NMPA Innovative Medical Device Special Review Program
04/09	European Heart Journal Publishes Individual-Patient-Data Analysis of TARGET-FIRST and ULTIMATE-DAPT: Aspirin Discontinuation One Month After PCI in Acute Myocardial Infarction
02/09	MicroPort Scientific : ® Coronary Announces FireShield™ Coronary Covered Stent System Enters NMPA Special Review Procedure for Innovative Medical Devices
31/08	MicroPort Scientific Corporation Delays Earnings Results Release for the Six Months Ended June 30, 2026
28/08	MicroPort Scientific : ® CardioFlow Announces Leadership Transition
28/08	MicroPort Scientific Corporation Announces Board and Committee Changes, Effective August 28, 2026
27/08	MicroPort Scientific : ® Endovastec™’s Aorfix™ Endograft System Granted NMPA Green Channel Designation for Innovative Medical Devices
13/08	MicroPort Scientific Expects to Record Loss in H1
12/08	MicroPort Scientific Corporation Provides Preliminary Consolidated Earnings Guidance for the Six Months Ended 30 June 2026
24/07	MicroPort Scientific : ® Enters into Letter of Intent with Tinavi for Potential Disposal of International Orthopedics Business
16/07	MicroPort Scientific Unit Eyes Sale of Controlling Stake in Orthopedics Business
30/06	MicroPort Scientific Corporation Appoints Dr. Yingyao Chen as an Independent Non-executive Director
29/06	MicroPort Scientific : CardioFlow Enrolls First Patients Worldwide in STARLIGHT Clinical Trial Evaluating the LINEA™ Pacing Lead for LBBAP
27/05	MicroPort Scientific : ® Appoints Greg Holman as Chief Commercial Officer
27/05	Microport Scientific Corporation Announces Appointment of Greg Holman to Chief Commercial Officer
21/05	Bayzed Health Unit Partners With MicroPort Units on Smart Healthcare Services
20/05	Bayzed Medical Investment Group Company Limited, Wholly Owned Subsidiary of Bayzed Health Group Inc Enters into Strategic Cooperation Agreements with Shanghai Weichuang Weilian Weitong Health Management Co., Ltd. and Shanghai Mingyue Medical Technology Co., Ltd, Subsidiaries of MicroPort Scientific Corporation
30/04	MicroPort Scientific Corporation Auditor Raises 'Going Concern' Doubt
29/04	Microport Scientific says qtrly net profit attributable for Shanghai Microport Endovascular Medtech (Group) RMB154.8 mln
08/04	Microport Cardioflow Medtech Corporation and Microport Scientific Corporation Enter Distribution Agreements for International Markets
01/04	MicroPort Scientific Turns to Profit in 2025
31/03	Microport Scientific says Zhaohua Chang will no longer serve as CEO
31/03	MicroPort Scientific posts FY profit attributable US$48.5 million
31/03	Microport Scientific Corporation Announces CEO Changes, Effective April 1, 2026
31/03	MicroPort Scientific Corporation Establishes Global Executive Committee